Compare GEHC & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEHC | TEVA |
|---|---|---|
| Founded | 1892 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8B | 30.2B |
| IPO Year | 2022 | N/A |
| Metric | GEHC | TEVA |
|---|---|---|
| Price | $81.10 | $33.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $91.17 | $37.25 |
| AVG Volume (30 Days) | 3.2M | ★ 7.1M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 4.84 | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $20,625,000,000.00 | N/A |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $4.53 | $2.97 |
| P/E Ratio | ★ $17.68 | $28.19 |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $57.65 | $12.47 |
| 52 Week High | $89.77 | $37.35 |
| Indicator | GEHC | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 53.33 |
| Support Level | $77.55 | $30.70 |
| Resistance Level | $85.76 | $35.32 |
| Average True Range (ATR) | 2.28 | 0.84 |
| MACD | 0.19 | -0.20 |
| Stochastic Oscillator | 48.71 | 33.82 |
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.